SELECT Trial Explained: Semaglutide Heart Outcomes and Tracking

Why heart outcomes matter for people on a GLP-1

Many people who use a GLP-1 tracker watch weight, appetite, and how they feel week to week. Heart risk is quieter day to day. Clinics usually judge it with blood pressure, labs, and a history of prior events.

In late 2023, the SELECT trial reported major cardiovascular results for weekly semaglutide in adults who already had cardiovascular disease, had overweight or obesity, and did not have diabetes. In March 2024, the U.S. Food and Drug Administration added a related indication for Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight, used with a reduced-calorie diet and increased physical activity.

Those headlines are useful. They are not a personal plan. Your licensed healthcare provider decides whether a GLP-1 fits your history. What you can control is the quality of the record you bring to that conversation.

What SELECT actually studied

SELECT was a large, randomized, double-blind, placebo-controlled cardiovascular outcomes trial published in the New England Journal of Medicine. Investigators enrolled 17,604 adults aged 45 or older with preexisting cardiovascular disease and a body-mass index of 27 or greater, without a history of diabetes. Participants were assigned to once-weekly subcutaneous semaglutide or placebo, on top of standard care for cardiovascular disease and lifestyle counseling.

The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Over a mean follow-up of about 39.8 months, a primary event occurred in 6.5% of people in the semaglutide group and 8.0% in the placebo group (hazard ratio 0.80; 95% CI 0.72 to 0.90; P<0.001). That is roughly a 20% relative reduction in the composite end point in this study population.

The FDA later summarized the same pattern: major adverse cardiovascular events occurred in 6.5% of participants who received Wegovy versus 8% who received placebo. Full methods and results are in the SELECT publication on PubMed, and the regulatory framing is in the FDA announcement on the cardiovascular indication.

A few details matter for how you read the news:

• SELECT enrolled people with established cardiovascular disease, not a general wellness population.
• Participants did not have diabetes at enrollment. Separate trials and labels cover type 2 diabetes uses of semaglutide.
• Both groups received standard cardiovascular care. The comparison was semaglutide versus placebo on that background.
• Gastrointestinal adverse events led to more permanent discontinuations in the semaglutide group than in the placebo group.

None of those points tells you what to take. They tell you what the evidence base looked like, so you can ask better questions.

How MedlinePlus describes related uses of semaglutide

For a plain-language overview, MedlinePlus covers semaglutide injection, including reducing the risk of heart attack, stroke, or death in adults who are obese or overweight and have heart and blood vessel disease. Confirm every detail with your provider. Your history may put you outside the groups studied in SELECT.

What a GLP-1 tracker is useful for after SELECT headlines

Providers still need a timeline: which product you used, when doses were logged, how weight moved, and which side effects showed up after which weeks.

A semaglutide tracker habit helps when you can answer questions like these from your own log instead of from memory:

• Which weeks did you take the dose on time, delay it, or miss it?
• How did weight trend across months, not just the last two weigh-ins?
• When did nausea, constipation, or other symptoms start relative to a change your provider made?
• Which injection sites you used, and whether any site stayed sore longer than usual?

Those answers support shared decisions. They do not replace blood pressure checks, lipid panels, imaging, or clinical judgment from a licensed clinician.

Records worth keeping for heart-risk conversations

Build a short packet you can open in the waiting room. Keep it boring and consistent.

Dose history

Log each dose with date and time, the product name your provider prescribed, and whether the dose was on time, late, or missed. A clean dose history makes adherence visible without a long story. Tie reminders to the same weekday pattern your provider set so the log stays honest. Peppy's dose reminders are one way to keep that cadence when life gets busy.

Weight next to the calendar

SELECT was a cardiovascular trial, not a pure weight-loss trial, yet weight still moved for many participants and remains a routine clinic metric. Chart weight on the same calendar as doses so your provider can see the trend beside adherence. Peppy's weight tracking view is built for that side-by-side look.

Side-effect notes with dates

GI symptoms were a common reason people stopped the study product in SELECT. Mild versus severe ratings, plus the date, help your provider see whether a symptom is new, lingering, or tied to another change. Do not self-diagnose pancreatitis, gallbladder issues, or eye changes from a blog post. Flag sudden or severe symptoms the way your care team asked you to.

Home readings and questions

If your provider asked you to log home blood pressure, pulse, or glucose, keep those readings in the same date range as your dose log. Write three short visit questions in advance, such as whether your history looks like the SELECT population, which labs to watch next, and what would lead the clinic to change or pause therapy.

Pens, vials, and numbers you already have

Some people use a multi-dose pen. Others use a compounded vial and a syringe. Record vial or pen strength, liquid volume when relevant, and the dose your provider gave you. If you need to recheck how those numbers turn into syringe units for a vial you mixed, Peppy's free peptide calculator works from the figures you enter and does not choose a dose for you.

What SELECT does not settle for you

SELECT does not mean every person with overweight should start a GLP-1. It does not rank semaglutide against every other option for your chart. It does not tell you how to handle a missed dose, planned surgery, pregnancy planning, or a new symptom. Those decisions stay with your clinician. The FDA note still frames the medicine as used with diet and activity changes, and SELECT participants received lifestyle counseling alongside study treatment.

A simple weekly routine that stays useful

1. Pick one weekday for your dose if that is the schedule your provider gave you, and protect it on your calendar.
2. Log the dose the same day, including late or missed entries instead of leaving blanks.
3. Weigh in on a consistent morning schedule if your clinic wants weight trends.
4. Note new or worsening symptoms with a date and severity word (mild, moderate, severe).
5. Before each visit, export or screenshot the last 8 to 12 weeks of doses, weight, and side-effect notes.

The trial gives population-level evidence. Your log gives visit-level context. Together, they help your provider decide what applies to you.

Bottom line

SELECT showed that, in adults with preexisting cardiovascular disease and overweight or obesity without diabetes, weekly semaglutide reduced a composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke compared with placebo over roughly three years of follow-up. Regulators later reflected that evidence in a cardiovascular risk-reduction indication for Wegovy in a related population, always alongside diet and activity guidance from the care team.

If you already use a GLP-1 under a provider's care, treat the news as a reason to tighten your records, not as a do-it-yourself protocol. Keep a reliable dose log, weight chart, and dated symptom notes. Bring them to appointments. Let your licensed healthcare provider connect the trial language to your own history.